UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

                               
FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  November 8, 2006

 

GENTA INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware
(State or Other Jurisdiction of Incorporation)

 

0-19635
(Commission File Number)

 

33-0326866
(IRS Employer Identification No.)

 

200 Connell Drive
Berkeley Heights, NJ
(Address of Principal Executive Offices)

 

07922
(Zip Code)

 

 

(908) 286-9800

 

(Registrant’s Telephone Number, Including Area Code)

                                                                                                           
(Former Name or Former Address, if Changed Since Last Report)

 

                               


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:


   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)


    Pre -commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))


    Pre -commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 

 


Item 8.01 Other Events.


On November 8, 2006, Genta Incorporated (NASDAQ: GNTA) issued a press release announcing the presentation of new analyses from the Company’s randomized Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).  In patients who were prospectively stratified as being “non-refractory”, Genasense-treated patients were four times more likely to achieve complete remission compared with patients treated with chemotherapy alone.  Moreover, these non-refractory patients also achieved a statistically significant increase in overall survival.


The press release is attached hereto as Exhibit 99.1and is incorporated herein by reference. The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


   
 

Exhibit
Number

 

Description

 

 

99.1

 

Press Release of the Company dated November 8, 2006










SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

GENTA INCORPORATED

Date:

November 8, 2006

 

By:

/s/ RICHARD J. MORAN

 

 

 

 

Name:

Richard J. Moran

 

 

 

 

Title:

Senior Vice President, Chief Financial Officer and Corporate Secretary







EXHIBIT INDEX

Exhibit
Number

Description

Sequentially
Numbered Page

99.1

Press Release of the Company dated November 8, 2006